Cooperation Invitation | Frost & Sullivan is about to release the '2026 China Diabetes Health Management Industry Development White Paper'.

Diabetes is one of the most burdensome chronic diseases worldwide. According to Frost & Sullivan’s analysis, the global number of diabetes patients in 2025 reached 710 million, with China having 250 million patients. However, awareness rates, treatment rates, and blood sugar control rates were only 36.7%, 32.9%, and 16.5%, respectively, indicating a significant gap between diagnosis and long-term management. With the implementation of policies such as the "Action Plan for Diabetes Prevention and Control (2024–2030)" and the advancement of medical insurance payment reforms, diabetes management is shifting from in-hospital treatment to out-of-hospital long-term management. Diabetes health management is no longer merely a single issue of blood sugar control but rather a key intersection of the construction of a chronic disease prevention and control system, the transformation of medical insurance payment, and the upgrade of the digital health industry.

Based on its long-term insights into the medical health and chronic disease management industry, Frost & Sullivan (hereafter referred to as "Frost & Sullivan") is about to release the "2026 White Paper on the Development of Diabetes Health Management Industry in China". The white paper will provide an in-depth understanding of the development trends of the diabetes health management industry from three perspectives: market space estimation, service chain value breakdown, and business model and competitive landscape comparison, offering a comprehensive perspective for those in the field.

This white paper, grounded in the Chinese market while considering a global view, systematically examines the epidemiological characteristics, complications, and disease burden of diabetes globally and in China, relevant health management policies, and the direction of medical insurance payment reform. It estimates the market size of diabetes health management and digital diabetes health management in China, and constructs a market driver model driven by expanding patient base, mature digital technology, and enhanced policy support and management objectives. Meanwhile, the white paper will outline the clinical definition, scientific basis, and evidence-based evidence for the progressive management objectives of "comprehensive compliance—drug reduction and discontinuation—relief" for type 2 diabetes, analyze the standardized progress of the integrated traditional Chinese medicine and Western medicine approach, and propose quality standards for high-quality diabetes health management.

On this basis, the white paper will systematically break down the service chain panorama and value aspects of screening and diagnosis, blood sugar monitoring, multi-dimensional intervention, follow-up and plan adjustment, drug reduction and discontinuation, and relief assessment, as well as the main business models such as monitoring device-based, digital therapy, out-of-hospital management, digital chronic disease platform, and insurance linkage. It will also examine the primary channels, end-to-end service process, and patient need stratification for digital diabetes health management, and analyze the service chain coverage depth and competitive landscape for each model. Additionally, the white paper will use digital health management based on traditional Chinese medicine as a typical practice to explore the mode characteristics and differentiated capabilities of the deep integration of specialized diagnosis and treatment, traditional Chinese medicine intervention, digital platform, and long-term follow-up.

Furthermore, the white paper will assess the industry’s development direction of "from diabetes to multiple chronic diseases, from individuals to families, from China to the world, from single-function to full-process management", analyze the current core bottlenecks and breakthrough pathways, and provide a reference for practitioners and investors. It will also showcase representative companies of different business types, systematically presenting their service models, business layout, and development history, as well as their core competitiveness and model features.

Frost & Sullivan sincerely invites outstanding companies in diabetes health management across different business types—such as monitoring devices, digital therapy, out-of-hospital management, digital chronic disease platform, and insurance linkage—to participate in the research and release of this white paper, enabling a rational expression and consensus-building on industry development within a professional analysis framework, and working together to promote the high-quality development of the diabetes health management industry in China.

As a systematic research outcome in the field of diabetes health management, this white paper will be widely published via Frost & Sullivan’s official website, media matrix, and vertical medical health channels. The report will deeply highlight the core advantages of the participating companies, focusing on the technical innovation of monitoring equipment and digital platforms, the breadth of service channels and patient coverage, the depth of multi-disciplinary team and full-process management closed loop, and the health outcome results such as improved blood sugar, reduced drug use and discontinuation, and lower complication risk. Through differentiated presentation, it will help the market establish a clear understanding of the companies’ professional capabilities and large-scale delivery capabilities, enhance industry influence and brand credibility, and provide a platform for authoritative voice and centralized display.

The white paper will establish an exchange platform connecting multiple parties across the diabetes health management industry chain, promoting deep interaction and resource alignment among companies with different positions. Companies such as those based on monitoring devices, digital therapy, out-of-hospital management, digital chronic disease platform, and insurance linkage can differentiate their businesses, facilitate the complementary combination of monitoring data, professional services, institutional channels, and payment capabilities, enhance mutual understanding with investment institutions and industrial partners, and create more opportunities for channel coordination, resource integration, and commercial expansion.

Based on the white paper’s systematic analysis of the upgrade of diabetes management paradigms, digital service models, and the industry’s competitive landscape, the professional expertise of the participating companies will be objectively presented. Through the detailed presentation of the research content, their recognition and influence in continuous blood sugar monitoring, AI risk early warning, multi-disciplinary collaborative intervention, integrated traditional Chinese medicine and Western medicine management, or health outcome evaluation will be enhanced, thereby solidifying their differentiated market positioning.

With Frost & Sullivan’s network of investment institutions and industrial partners in the medical health sector, the release of the white paper will effectively increase a company’s visibility and connect with various types of diverse capital. Digital health companies in the stage of product and model validation can reach VC/PE interested in technology and model innovation; companies in the commercial scaling stage can connect with industrial capital and strategic investments from pharmaceutical and medical device leaders who focus on channel coordination and payment closed loop; companies that have already developed scaled service capabilities can attract strategic investors interested in long-term health outcomes and operational quality. The white paper will serve as a communication bridge between companies and diverse capital, enabling them to take the initiative in financing, business cooperation, mergers and acquisitions, and listing planning.

Based on the deep communication established through the white paper, Frost & Sullivan can work with the participating companies to explore diverse collaborative directions, including brand communication, investment and financing consulting, growth strategy, expansion into multiple chronic diseases, and overseas deployment. The two parties may establish a long-term partnership on this basis, jointly addressing industry changes and working together to promote the high-quality development of the diabetes health management industry.

Scan the QR code below to register for the case collection and selection process